中风患者血压的管理

Philip B. Gorelick , Shakaib Qureshi , Muhammad U. Farooq
{"title":"中风患者血压的管理","authors":"Philip B. Gorelick ,&nbsp;Shakaib Qureshi ,&nbsp;Muhammad U. Farooq","doi":"10.1016/j.ijchy.2019.100021","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>In this review and opinion piece, we discuss recent United States (US)-based guidance statements on the management of BP in stroke according to stroke type and stage of stroke.</p></div><div><h3>Methods</h3><p>We reviewed the most recent guidance statements on BP control from United States (US)-based organizations such as the American Heart Association/American Stroke Association (AHA/ASA) and American College of Cardiology (ACC), and articles available to the authors in their personal files.</p></div><div><h3>Results</h3><p>The key BP target before starting alteplase (t-PA) is &lt; 185/110 mm Hg, and the maintenance BP after tPA administration is &lt; 180/105 mm Hg. For IPH patients with systolic BP between 150 and 220 mm Hg and no contraindication to acute BP reduction therapy, acute lowering to 140 mm Hg systolic BP is safe. For persons with small vessel or lacunar cerebral ischemia, a reasonable BP lowering target is &lt; 130 mm Hg systolic. For primary stroke prevention, the target BP for those with hypertension is &lt; 140/90 mm Hg and self-measured BP is recommended to assist in BP control. Recent study and guidance suggest a BP target of &lt;130/80 mm Hg for both primary and recurrent stroke prevention. BP control is reasonable for the prevention of cognitive decline or dementia.</p></div><div><h3>Conclusions</h3><p>BP targets for the proper management of stroke vary by chronological stage of stroke and by stroke subtype. Furthermore, consideration should be given to control of BP variability, especially in the acute phases of stroke, as it may play a role in conferring longer term outcomes.</p></div>","PeriodicalId":36839,"journal":{"name":"International Journal of Cardiology: Hypertension","volume":"3 ","pages":"Article 100021"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijchy.2019.100021","citationCount":"9","resultStr":"{\"title\":\"Management of blood pressure in stroke\",\"authors\":\"Philip B. Gorelick ,&nbsp;Shakaib Qureshi ,&nbsp;Muhammad U. Farooq\",\"doi\":\"10.1016/j.ijchy.2019.100021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>In this review and opinion piece, we discuss recent United States (US)-based guidance statements on the management of BP in stroke according to stroke type and stage of stroke.</p></div><div><h3>Methods</h3><p>We reviewed the most recent guidance statements on BP control from United States (US)-based organizations such as the American Heart Association/American Stroke Association (AHA/ASA) and American College of Cardiology (ACC), and articles available to the authors in their personal files.</p></div><div><h3>Results</h3><p>The key BP target before starting alteplase (t-PA) is &lt; 185/110 mm Hg, and the maintenance BP after tPA administration is &lt; 180/105 mm Hg. For IPH patients with systolic BP between 150 and 220 mm Hg and no contraindication to acute BP reduction therapy, acute lowering to 140 mm Hg systolic BP is safe. For persons with small vessel or lacunar cerebral ischemia, a reasonable BP lowering target is &lt; 130 mm Hg systolic. For primary stroke prevention, the target BP for those with hypertension is &lt; 140/90 mm Hg and self-measured BP is recommended to assist in BP control. Recent study and guidance suggest a BP target of &lt;130/80 mm Hg for both primary and recurrent stroke prevention. BP control is reasonable for the prevention of cognitive decline or dementia.</p></div><div><h3>Conclusions</h3><p>BP targets for the proper management of stroke vary by chronological stage of stroke and by stroke subtype. Furthermore, consideration should be given to control of BP variability, especially in the acute phases of stroke, as it may play a role in conferring longer term outcomes.</p></div>\",\"PeriodicalId\":36839,\"journal\":{\"name\":\"International Journal of Cardiology: Hypertension\",\"volume\":\"3 \",\"pages\":\"Article 100021\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ijchy.2019.100021\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Cardiology: Hypertension\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590086219300217\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cardiology: Hypertension","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590086219300217","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 9

摘要

目的在这篇综述和观点文章中,我们讨论了最近基于美国的根据卒中类型和卒中阶段管理卒中患者BP的指导声明。方法我们查阅了美国心脏协会/中风协会(AHA/ASA)和美国心脏病学会(ACC)等美国组织关于血压控制的最新指导声明,以及作者个人档案中可获得的文章。结果阿替普酶(t-PA)启动前的关键血压指标为<185/110 mm Hg, tPA给药后维持血压<对于收缩压在150 - 220毫米汞柱之间且无急性降压治疗禁忌症的IPH患者,急性降压至140毫米汞柱是安全的。对于小血管或腔隙性脑缺血患者,合理的降压目标为<收缩压130mmhg。对于初级脑卒中预防,高血压患者的目标血压为<建议140/90毫米汞柱和自测血压,以帮助控制血压。最近的研究和指南建议原发性和复发性卒中预防的血压目标为130/80 mm Hg。控制血压对于预防认知能力下降或痴呆是合理的。结论不同的脑卒中时间分期和不同的脑卒中亚型对脑卒中合理治疗的血压指标不同。此外,应考虑控制血压变异性,特别是在中风的急性期,因为它可能在授予长期结果中发挥作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Management of blood pressure in stroke

Objective

In this review and opinion piece, we discuss recent United States (US)-based guidance statements on the management of BP in stroke according to stroke type and stage of stroke.

Methods

We reviewed the most recent guidance statements on BP control from United States (US)-based organizations such as the American Heart Association/American Stroke Association (AHA/ASA) and American College of Cardiology (ACC), and articles available to the authors in their personal files.

Results

The key BP target before starting alteplase (t-PA) is < 185/110 mm Hg, and the maintenance BP after tPA administration is < 180/105 mm Hg. For IPH patients with systolic BP between 150 and 220 mm Hg and no contraindication to acute BP reduction therapy, acute lowering to 140 mm Hg systolic BP is safe. For persons with small vessel or lacunar cerebral ischemia, a reasonable BP lowering target is < 130 mm Hg systolic. For primary stroke prevention, the target BP for those with hypertension is < 140/90 mm Hg and self-measured BP is recommended to assist in BP control. Recent study and guidance suggest a BP target of <130/80 mm Hg for both primary and recurrent stroke prevention. BP control is reasonable for the prevention of cognitive decline or dementia.

Conclusions

BP targets for the proper management of stroke vary by chronological stage of stroke and by stroke subtype. Furthermore, consideration should be given to control of BP variability, especially in the acute phases of stroke, as it may play a role in conferring longer term outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
International Journal of Cardiology: Hypertension
International Journal of Cardiology: Hypertension Medicine-Cardiology and Cardiovascular Medicine
CiteScore
0.40
自引率
0.00%
发文量
0
审稿时长
13 weeks
期刊最新文献
COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system Reduced global longitudinal strain at rest and inadequate blood pressure response during exercise treadmill testing in male heterozygous familial hypercholesterolemia patients Association of family history with incidence and gestational hypertension outcomes of preeclampsia Critical questions in cardiovascular risk: What nutrition labels should be used on food? Why is salt-sensitivity of blood pressure, a known cardiovascular risk factor, not treated?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1